Mutual Advisors LLC bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,258 shares of the company’s stock, valued at approximately $275,000.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. RFG Advisory LLC lifted its position in shares of Tempus AI by 19.9% during the 2nd quarter. RFG Advisory LLC now owns 45,372 shares of the company’s stock worth $2,883,000 after buying an additional 7,530 shares during the period. Axxcess Wealth Management LLC raised its position in Tempus AI by 6.2% in the 2nd quarter. Axxcess Wealth Management LLC now owns 8,190 shares of the company’s stock valued at $520,000 after purchasing an additional 481 shares during the last quarter. Atria Wealth Solutions Inc. bought a new position in Tempus AI in the 2nd quarter valued at $214,000. Concord Wealth Partners raised its position in Tempus AI by 308.0% in the 2nd quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after purchasing an additional 308 shares during the last quarter. Finally, Total Clarity Wealth Management Inc. bought a new position in Tempus AI in the 2nd quarter valued at $666,000. Institutional investors own 24.22% of the company’s stock.
Insider Activity at Tempus AI
In other news, Director Theodore Leonsis sold 44,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $69.90, for a total transaction of $3,075,600.00. Following the completion of the transaction, the director directly owned 86,756 shares of the company’s stock, valued at $6,064,244.40. This represents a 33.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew Polovin sold 5,398 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $74.65, for a total value of $402,960.70. Following the transaction, the executive vice president directly owned 132,056 shares of the company’s stock, valued at $9,857,980.40. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 933,662 shares of company stock valued at $68,070,993 over the last ninety days. Company insiders own 26.27% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Stock Report on TEM
Tempus AI Stock Down 3.6%
Shares of Tempus AI stock opened at $89.10 on Wednesday. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $104.32. The business has a fifty day simple moving average of $83.27 and a 200 day simple moving average of $66.88. The stock has a market cap of $15.48 billion, a PE ratio of -74.87 and a beta of 4.87.
Tempus AI (NASDAQ:TEM – Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The firm had revenue of $314.64 million during the quarter, compared to analysts’ expectations of $296.84 million. During the same period in the previous year, the firm earned ($6.86) earnings per share. The company’s revenue was up 89.5% on a year-over-year basis. Tempus AI has set its FY 2025 guidance at EPS. Research analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.
Tempus AI Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Articles
- Five stocks we like better than Tempus AI
- The Most Important Warren Buffett Stock for Investors: His Own
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- Using the MarketBeat Stock Split Calculator
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
- Options Trading – Understanding Strike Price
- Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.